C o r r e s p o n d e n c e
Antidrug Antibodies in Patients Treated with Alirocumab
To the Editor: Immunogenicity led to the dis continuation of clinical development of boco cizumab, a murinederived, humanized antibody to proprotein convertase subtilisin-kexin type 9 (PCSK9), as now described by Ridker et al. 1 in the Journal. Evidence suggests increased immuno genicity potential for murinederived antibodies humanized by artificially engineering them in vitro, as compared with fully human antibodies that are produced with the use of mice with genetically humanized immune systems.
Very low rates of immunogenicity were ob served in clinical trials of alirocumab, a fully hu man PCSK9 antibody derived from VelocImmune mice (in which the murine genes in the heavy chain and lightchain immunoglobulin variable region are replaced with their human counter parts). 24 We evaluated the effect of antidrug antibodies on the safety and efficacy of alirocu mab with respect to reductions in levels of low density lipoprotein (LDL) cholesterol using data from 10 trials involving 4747 patients (Tables S1 and S2 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Antidrug antibodies were assessed with the use of a validated assay with positivity set to maximize sensitivity, which resulted in false positives in a low percentage of baseline and control samples.
Antidrug antibodies were observed in 155 of 3039 patients (5.1%) in the alirocumab group and in 17 of 1708 (1.0%) in the control group. Persistent antidrug antibodies (i.e., ≥2 consecu tive positive samples over ≥12 weeks) were found in 44 patients (1.4%) in the alirocumab group and in 3 (0.2%) in the control group (Table S3 in the Supplementary Appendix). To evaluate the potential effect of antidrug antibodies on effi cacy, we compared patients without antidrug antibodies with those who had persistent or transient antidrug antibodies using a mixed effect model with repeated measures (Fig. 1 , and the Methods section in the Supplementary Ap pendix).
According to regulatory guidance, 5 we rea soned that the presence of persistent antidrug antibodies would most likely influence efficacy. However, we found that substantial reductions in LDL cholesterol levels were maintained over the course of the studies, regardless of antidrug antibody status, although for some time points, nominally significant differences (not adjusted for multiple testing) were noted ( Fig. 1 , and Ta ble S4 in the Supplementary Appendix). In a trend analysis, no late loss in the LDLcholesterol re sponse was seen in patients with antidrug anti bodies. Mean reductions in LDL cholesterol were also maintained over time in patients with neu tralizing antibodies (antidrug antibodies that inhibit binding), which were observed in 1.3% of the patients (Table S5 and (mostly mild) were more frequent among the patients with antidrug antibodies ( Table S6 in the Supplementary Appendix).
In conclusion, antidrug antibodies developed in few patients who were treated with alirocumab, and even those patients had substantial and du rable evidence of LDLcholesterol lowering. How ever, these findings are limited by the small number of patients in whom antidrug antibodies developed. Since immunogenicity data are depen dent on numerous factors, comparisons of anti drugantibody incidence among different drugs (even in the same class) may be misleading. Panel A shows data from ODYSSEY LONG TERM, which involved patients who received 150 mg of alirocumab every 2 weeks. Panel B shows the results of a meta-analysis of eight phase 3 ODYSSEY trials (FH I, FH II, COMBO I, COMBO II, OPTIONS I, OPTIONS II, MONO, and ALTERNATIVE) in which patients received 75 mg of alirocumab every 2 weeks with a possible dose increase to 150 mg every 2 weeks, depending on the low-density lipoprotein (LDL) cholesterol level at 8 weeks. (References for all the trials cited here are provided in the Supplementary Appendix.) Although immunogenicity data were compiled from 10 studies involving all 4747 patients, the 10th trial (ODYSSEY HIGH FH) was not included in the efficacy analyses, since it did not have any patients with persistent antidrug antibodies (i.e., those occurring in ≥2 consecutive samples over ≥12 weeks). Transient antidrug antibodies include those that were defined as either indeterminate (present only at the last sampling time point) or transient (any positive antidrug-antibody response that was considered to be neither persistent nor indeterminate 
